Na Nakorn Piyada, Pannengpetch Supitcha, Isarankura-Na-Ayudhya Patcharee, Thippakorn Chadinee, Lawung Ratana, Sathirapongsasuti Nuankanya, Kitiyakara Chagriya, Sritara Piyamitr, Vathesatogkit Prin, Isarankura-Na-Ayudhya Chartchalerm
Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand.
Center for Research and Innovation, Faculty of Medical Technology, Mahidol University, Nakornpathom, Thailand.
EXCLI J. 2020 Jun 24;19:872-891. doi: 10.17179/excli2020-1396. eCollection 2020.
Diabetic nephropathy, a major complication of diabetes mellitus (DM), is increasing worldwide and the large majority of patients have type 2 DM. Microalbuminuria has been used as a diagnostic marker of diabetic nephropathy. But owing to its insufficient sensitivity and specificity, other biomarkers are being sought. In addition, the pathophysiology of diabetic nephropathy is not fully understood and declines in renal function occur even without microalbuminuria. In this study, we investigated urinary proteins from three study groups (controls, and type 2 diabetic subjects with or without microalbuminuria). Non-targeted label-free Nano-LC QTOF analysis was conducted to discover underlying mechanisms and protein networks, and targeted label-free Nano-LC QTOF with SWATH was performed to qualify discovered protein candidates. Twenty-eight proteins were identified as candidates and functionally analyzed via String DB, gene ontology and pathway analysis. Four predictive mechanisms were analyzed: i) response to stimulus, ii) platelet activation, signaling and aggregation, iii) ECM-receptor interaction, and iv) angiogenesis. These mechanisms can provoke kidney dysfunction in type 2 diabetic patients via endothelial cell damage and glomerulus structural alteration. Based on these analyses, three proteins (kininogen-1, basement membrane-specific heparan sulfate proteoglycan core protein, and roundabout homolog 4) were proposed for further study as potential biomarkers. Our findings provide insights that may improve methods for both prevention and diagnosis of diabetic nephropathy.
糖尿病肾病是糖尿病(DM)的一种主要并发症,在全球范围内呈上升趋势,并且绝大多数患者患有2型糖尿病。微量白蛋白尿一直被用作糖尿病肾病的诊断标志物。但由于其敏感性和特异性不足,人们正在寻找其他生物标志物。此外,糖尿病肾病的病理生理学尚未完全阐明,即使没有微量白蛋白尿,肾功能也会下降。在本研究中,我们调查了三个研究组(对照组、有或无微量白蛋白尿的2型糖尿病患者)的尿蛋白。进行了非靶向无标记的纳升液相色谱-四极杆飞行时间质谱分析以发现潜在机制和蛋白质网络,并使用数据独立采集的靶向无标记纳升液相色谱-四极杆飞行时间质谱对发现的蛋白质候选物进行鉴定。鉴定出28种蛋白质作为候选物,并通过STRING数据库、基因本体论和通路分析进行功能分析。分析了四种预测机制:i)对刺激的反应,ii)血小板活化、信号传导和聚集,iii)细胞外基质-受体相互作用,以及iv)血管生成。这些机制可通过内皮细胞损伤和肾小球结构改变引发2型糖尿病患者的肾功能障碍。基于这些分析,提出了三种蛋白质(激肽原-1、基底膜特异性硫酸乙酰肝素蛋白聚糖核心蛋白和轴突导向分子同源物4)作为潜在生物标志物进行进一步研究。我们的研究结果提供了可能改善糖尿病肾病预防和诊断方法的见解。